Session 5: Immunology and Immunotherapy

Chair(s)

• 

  Herbert Ho Fung Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine) (he/him/his)

  Clinical Associate Professor
  The Chinese University of Hong Kong
  Hong Kong, Hong Kong

Moderator(s)

• 

  Neeta Somaiah, MD (she/her/hers)

  Associate Professor and Deputy Chair
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• 

  Everett Moding, MD, PhD (he/him/his)

  Assistant Professor
  Stanford University
  Stanford, California, United States
• JM

  Javier Martin-Broto, MD, PhD (he/him/his)

  Medical oncology
  Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz and Villalba General Hospital, Madrid, Spain; Medical Oncology
  Madrid, Madrid, Spain

Presentations:

• 9:00 AM – 10:00 AM  

  OUTCOMES OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA TREATED WITH AFAMITRESGENE AUTOLEUCEL ("AFAMI-CEL")
  

  Author: Brian Andrew Van Tine, MD, PhD (he/him/his) – Washington University School of Medicine

  Co-Author: Kristen N. Ganjoo, MD – Stanford Cancer Center

  Co-Author: Jean-Yves Blay, MD, PhD – Centre Léon-Bérard

  Co-Author: Claudia Valverde, MD – Vall D’Hebron University Hospital

  Co-Author: Dejka M. Araujo, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Albiruni Ryan Abdul Razak, MB BCh, BM BCh – Princess Margaret Cancer Center

  Co-Author: Axel Le Cesne, MD – Gustave Roussy Institute

  Co-Author: Scott M. Schuetze, MD, PhD – University of Michigan

  Co-Author: Michael J. Wagner, MD – University of Washington/Fred Hutch/Seattle Cancer Care Alliance

  Co-Author: Steven Attia, D.O. – Mayo Clinic

  Co-Author: Edouard Forcade, MD – Service d'Hématologie Clinique et Thérapie Cellulaire, CHU

  Co-Author: Mihaela Druta, MD – H. Lee Moffitt Cancer Center and Research Institute

  Co-Author: Seth Pollack, MD – Robert H. Lurie Comprehensive Cancer Center of Northwestern University

  Co-Author: Jane Bai, MS – Adaptimmune

  Co-Author: Paige Bayer, BS – Adaptimmune

  Co-Author: Erin Van Winkle, BS – Adaptimmune

  Co-Author: Elliot Norry, MD – Adaptimmune

  Co-Author: Colin Lunt, BSc (he/him/his) – Adaptimmune

  Co-Author: Dennis Williams, PharmD – Adaptimmune

  Co-Author: Sandra P. D'Angelo, MD – Memorial Sloan Kettering Cancer Center
• 9:00 AM – 10:00 AM  

  EFFICACY AND SAFETY OF BOTENSILIMAB PLUS BALSTILIMAB COMBINATION THERAPY IN REFRACTORY METASTATIC SARCOMA PATIENTS: FINDINGS FROM AN ONGOING EXPANDED PHASE 1B STUDY
  

  Author: Breelyn A. Wilky, MD (she/her/hers) – University of Colorado Cancer Center

  Co-Author: Jonathan Trent, MD, PhD – Sylvester Comprehensive Cancer Center, University of Miami

  Co-Author: Michael S. Gordon, MD – HonorHealth Research Institute

  Co-Author: Anthony B. El-Khoueiry, MD – University of Southern California Norris Comprehensive Cancer Center

  Co-Author: Andrea J. Bullock, MD – Beth Israel Deaconess Medical Center

  Co-Author: Brian S. Henick, MD – Herbert Irving Comprehensive Cancer Center at Columbia University School of Medicine

  Co-Author: Gary K. Schwartz, MD – Herbert Irving Comprehensive Cancer Center at Columbia University School of Medicine

  Co-Author: Mark Agulnik, MD (he/him/his) – City of Hope, Department of Medical Oncology & Therapeutics Research

  Co-Author: Daruka Mahadevan, MD, PhD (he/him/his) – UT Health San Antonio

  Co-Author: Jaymin M. Patel, MD – Agenus Inc.

  Co-Author: Joseph E. Grossman, MD (he/him/his) – Agenus Inc.

  Co-Author: Katherine Rosenthal, RN, MSN, OCN, CCRP – Agenus Inc.

  Co-Author: Steven J. O’Day, MD (he/him/his) – Agenus Inc.

  Co-Author: Apostolia M. Tsimberidou, MD, PhD – The University of Texas MD Anderson Cancer Center
• 9:00 AM – 10:00 AM  

  IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE VASCULAR SARCOMAS COHORT. A GEIS, ISG AND UCL STUDY.
  

  Author: Nadia Hindi, MD, MSc – Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz and Villalba General Hospital, Madrid, Spain; Medical Oncology

  Co-Author: Javier Martinez-Trufero, MD – HU Miguel Servet

  Co-Author: Giovanni Grignani, MD – Candiolo Cancer Institute, FPO – IRCCS

  Co-Author: Ana Sebio, MD, PhD (she/her/hers) – Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

  Co-Author: Sandra Strauss, MD, PhD – University Collegue of London (UCL)

  Co-Author: Silvia Stacchiotti, MD (she/her/hers) – Department of Medical Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  Co-Author: Enrique Gonzalez-Billalabeitia, MD – HU Doce de Octubre

  Co-Author: Irene Carrasco Garcia, MD – Virgen del Rocio University Hospital

  Co-Author: Rafael Ramos, MD, PhD – HU Son Espases

  Co-Author: Antonio Gutierrez, MD, PhD – HU Son Espases

  Co-Author: David S. Moura, PhD (he/him/his) – Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM),

  Co-Author: Patricio Ledesma, . – Sofpromed

  Co-Author: Javier Martin-Broto, MD, PhD (he/him/his) – Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz and Villalba General Hospital, Madrid, Spain; Medical Oncology
• 9:00 AM – 10:00 AM  

  A PHASE I TRIAL OF LYMPHODEPLETION PLUS ADOPTIVE CELL THERAPY WITH TUMOR INFILTRATING LYMPHOCYTES FOLLOWED BY HIGH-DOSE IL-2 IN ADOLESCENT AND YOUNG ADULT PATIENTS WITH SOFT TISSUE SARCOMA
  

  Author: John Mullinax, MD – Moffitt Cancer Center

  Co-Author: Jonathan Hensel, PhD – Quorum Innovations

  Co-Author: Madeline Rodriguez-Valentin, PhD – Moffitt Cancer Center

  Co-Author: Alejandro Alfaro, BS – Moffitt Cancer Center

  Co-Author: Elizabeth Rau, BS – Moffitt Cancer Center

  Co-Author: Damon Reed, MD – Moffitt Cancer Center

  Co-Author: Andrew Brohl, MD (he/him/his) – Moffitt Cancer Center

  Co-Author: Mihaela Druta, MD – H. Lee Moffitt Cancer Center and Research Institute

  Co-Author: Ricardo Gonzalez, MD – Moffitt Cancer Center

  Co-Author: Eric Toloza, MD, PhD – Moffitt Cancer Center

  Co-Author: Cheryl Cox, MS – Moffitt Cancer Center

  Co-Author: Amod Sarnaik, MD – Moffitt Cancer Center

  Co-Author: Shari Pilon-Thomas, PhD – Moffitt Cancer Center
• 9:00 AM – 10:00 AM  

  A PHASE II STUDY OF DURVALUMAB AND TREMELIMUMAB IN PATIENTS WITH ADVANCED OSTEOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
  

  Author: Shantanu Banerji, MD, FRCPC (he/him/his) – CancerCare Manitoba

  Co-Author: Abha Gupta, MD MSc – Princess Margaret Cancer Center

  Co-Author: Albiruni Ryan Abdul Razak, MB BCh, BM BCh – Princess Margaret Cancer Center

  Co-Author: Thierry Alcindor, MD – Harvard University,, Dana-Farber Cancer Center

  Co-Author: Quincy Chu, MD – Cross Cancer Institute

  Co-Author: Karen A. Gelmon, MD (she/her/hers) – BC Cancer

  Co-Author: Garth Nicholas, MD – Ottawa Hospital Research Institute

  Co-Author: Eric Winquist, MD (he/him/his) – Western University

  Co-Author: Kamal Haider, MD – Saskatoon Cancer Centre

  Co-Author: Torsten O. Nielsen, MD, PhD – Department of Pathology and Laboratory Medicine, University of British Columbia

  Co-Author: Ming Tsao, MD, FRCPC – Princess Margaret Cancer Centre

  Co-Author: Tricia Cottrell, MD – Canadian Cancer Trials Group

  Co-Author: Joana Sederias, n/a – Canadian Cancer Trials Group

  Co-Author: Siwei Zhang, n/a – Canadian Cancer Trials Group

  Co-Author: Wei Tu, n/a – Canadian Cancer Trials Group

  Co-Author: Janet Dancey, MD – Canadian Cancer Trials Group